|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Sat., Mar. 28, 6:59 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #3 of 25 |
Slide #3. Hoth Therapeutics Inc. — Secondary Offering
Company:
Hoth Therapeutics Inc. (NASDAQ:HOTH)
Date announced:
3/23/2020
Shares Offered:
1,449,275
Date of Pricing:
3/24/2020
Price Per Share:
$3.45
Secondary Offering Details:
Hoth Therapeutics Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/24- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering of 1,449,275 shares of its common stock at a price to the public of $3.45 per share. Hoth expects to receive aggregate gross proceeds of approximately $5 million from the offering, before deducting the underwriting discount and estimated offering expenses. The offering is expected to close on or about March 26, 2020, subject to customary closing conditions.
Hoth Therapeutics is a biopharmaceutical company. Co.'s primary asset is a sublicense agreement with Chelexa Biosciences, Inc. (Chelexa) pursuant to which Chelexa has granted Co. sublicense to make, use, have made, import, offer for sale, and sell products based upon or involving the use of: topical compositions comprising a zinc chelator and gentamicin; and zinc chelators to inhibit biofilm formation (the BioLexa Platform). In addition, Chelexa granted Co. the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, provide for sale, and sell products based upon the BioLexa Platform.
Open the HOTH Page at The Online Investor »
|
|||||||||||||||||||||
Open the HOTH Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.